Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
HILS

HILS - Hillstream BioPharma, Inc. Stock Price, Fair Value and News

1816.00USD-12.00 (-0.66%)Market Closed

Market Summary

HILS
USD1816.00-12.00
Market Closed
-0.66%

HILS Stock Price

View Fullscreen

HILS RSI Chart

HILS Valuation

Market Cap

22.5B

Price/Earnings (Trailing)

-2.5K

Price/Sales (Trailing)

104.0K

Price/Free Cashflow

-3.4K

HILS Price/Sales (Trailing)

HILS Profitability

Return on Equity

-126.07%

Return on Assets

-100%

Free Cashflow Yield

-0.03%

HILS Fundamentals

HILS Revenue

Revenue (TTM)

216.3K

Rev. Growth (Qtr)

66.1%

HILS Earnings

Earnings (TTM)

-8.9M

Earnings Growth (Yr)

16.08%

Earnings Growth (Qtr)

8.8%

Breaking Down HILS Revenue

Last 7 days

-4.8%

Last 30 days

-0.8%

Last 90 days

9.8%

Trailing 12 Months

465779.9%

How does HILS drawdown profile look like?

HILS Financial Health

Current Ratio

4.84

HILS Investor Care

Shares Dilution (1Y)

2.39%

Diluted EPS (TTM)

-4.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024216.3K000
2023000152.6K

Tracking the Latest Insider Buys and Sells of Hillstream BioPharma, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 14, 2022
appajosyula sireesh
gifted
-
-
-75,757
-
Jul 14, 2022
appajosyula sireesh
gifted
-
-
7,576
-
Jun 17, 2022
milby randy
bought
389
0.7799
500
chief executive officer
Jun 06, 2022
milby randy
bought
688
0.688463
1,000
chief executive officer
Jun 01, 2022
milby randy
bought
0.94
0.94
1.00
chief executive officer
May 25, 2022
milby randy
bought
786
0.786
1,000
chief executive officer
May 20, 2022
milby randy
bought
918
0.91825
1,000
chief executive officer
May 19, 2022
milby randy
bought
907
0.90765
1,000
chief executive officer
Apr 18, 2022
milby randy
acquired
24,341
0.101203
240,526
chief executive officer
Jan 14, 2022
milby randy
acquired
884,125
3.2
276,289
chief executive officer

1–10 of 14

Which funds bought or sold HILS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-53,000
-
-%
May 15, 2024
CITADEL ADVISORS LLC
sold off
-100
-10,041
-
-%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
new
-
4,481
4,481
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
new
-
5,464
5,464
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
11.25
-42.00
646
-%
May 13, 2024
RENAISSANCE TECHNOLOGIES LLC
new
-
6,000
6,000
-%
May 13, 2024
XTX Topco Ltd
new
-
7,361
7,361
-%
May 10, 2024
JPMORGAN CHASE & CO
new
-
1.00
1.00
-%
May 10, 2024
WELLS FARGO & COMPANY/MN
added
325
4.00
7.00
-%
May 06, 2024
Warberg Asset Management LLC
unchanged
-
-788
4,303
-%

1–10 of 11

Are Funds Buying or Selling HILS?

Are funds buying HILS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HILS
No. of Funds

Unveiling Hillstream BioPharma, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
tang capital partners lp
0.0%
0
SC 13G/A
Dec 07, 2023
tang capital partners lp
9.99%
252,549
SC 13G

Recent SEC filings of Hillstream BioPharma, Inc.

View All Filings
Date Filed Form Type Document
Jun 12, 2024
S-8
Employee Benefits Plan
Jun 11, 2024
8-K
Current Report
Jun 07, 2024
8-K
Current Report
Jun 07, 2024
424B5
Prospectus Filed
May 22, 2024
8-K
Current Report
May 14, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
Mar 22, 2024
DEFA14A
DEFA14A
Mar 22, 2024
ARS
ARS
Mar 21, 2024
DEFA14A
DEFA14A

Peers (Alternatives to Hillstream BioPharma, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Hillstream BioPharma, Inc. News

Latest updates
Defense World31 May 202406:17 am
Genetic Engineering & Biotechnology News16 months ago

Hillstream BioPharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q1
Revenue66.1%96.0058.0028.0034.0032.00
Operating Expenses-7.3%2,3472,5311,8452,3652,714
  S&GA Expenses-14.1%1,3221,5381,3571,3341,667
  R&D Expenses3.3%1,0259934881,0311,048
Interest Expenses1227.7%5.00354*3.007.006.00
Net Income8.8%-2,256-2,473-1,820-2,336-2,688
Net Income Margin32.7%-41.09*-61.06*---
Free Cashflow-99.6%-2,825-1,415-900-1,500-3,500
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42020Q4
Assets-18.8%8,88710,9463,1674,5994,7226,6898,01810,24812,091622-
  Current Assets-18.8%8,88710,9463,1674,5994,7226,6898,01810,24812,091622295
    Cash Equivalents-22.9%8,42710,9352,6893,9043,5696,5117,5979,48411,1224.00192
Liabilities1.3%1,8381,8151,4101,5301,5211,1459021,2081,7525,3074,012
  Current Liabilities1.3%1,8381,8151,4101,5301,5211,1459021,2081,7524,5342,725
Shareholder's Equity-22.8%7,0499,1311,7573,0693,2015,5447,1169,04010,339--
  Retained Earnings-9.1%-26,959-24,703-22,229-20,409-18,100-15,384-13,617-11,490-9,853-6,911-4,704
  Additional Paid-In Capital0.5%34,07833,90424,05523,54721,34220,99820,79520,55420,1912,226986
Shares Outstanding0.4%11,79011,74017,51216,81411,514-11,24811,57310,5746,3576,357
Float----3,900---5,600---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Cashflow From Operations-99.6%-2,825-1,415-884-1,535-3,464-892-1,548-1,388-2,728-7.67-316-269-492-
  Share Based Compensation-9.9%15417015815834520224133919.007.004.00554674-
Cashflow From Financing-96.7%3179,662-3061,846523-193-338-26413,860-33.06333276323-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

HILS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses  
Research and development$ 1,025,258$ 1,047,677
General and administrative1,322,0451,666,721
Total operating expenses2,347,3032,714,398
Loss from operations(2,347,303)(2,714,398)
Other income (expense)  
Interest expense(4,700)(6,138)
Interest income95,89432,248
Total other income (expense), net91,19426,110
Net loss$ (2,256,109)$ (2,688,288)
Net loss per share:  
Basic$ (0.19)$ (5.84)
Diluted$ (0.19)$ (5.84)
Weighted average number of common shares outstanding:  
Basic11,757,808460,580
Diluted11,757,808460,580

HILS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash$ 8,427,290$ 10,935,352
Prepaid expenses and other current assets460,00711,041
Total current assets8,887,29710,946,393
Total assets8,887,29710,946,393
Current liabilities  
Accounts payable993,244908,577
Accrued expenses527,527906,469
Insurance premium financing liability317,119
Total current liabilities1,837,8901,815,046
Total liabilities1,837,8901,815,046
Commitments and contingencies (see Note 5)
Stockholders’ equity  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized, 11,793,309 shares and 11,743,309 shares issued and 11,789,676 shares and 11,739,676 shares outstanding as of March 31, 2024 and December 31, 2023, respectively1,1801,175
Additional paid-in capital34,077,82733,903,663
Accumulated deficit(26,959,635)(24,703,526)
Treasury stock, at cost, 3,633 shares held in treasury as of March 31, 2024 and December 31, 2023(69,965)(69,965)
Total stockholders’ equity7,049,4079,131,347
Total liabilities and stockholders’ equity$ 8,887,297$ 10,946,393
HILS
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
 CEO
 WEBSITEhillstreambio.com
 INDUSTRYBiotechnology
 EMPLOYEES1

Hillstream BioPharma, Inc. Frequently Asked Questions


What is the ticker symbol for Hillstream BioPharma, Inc.? What does HILS stand for in stocks?

HILS is the stock ticker symbol of Hillstream BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hillstream BioPharma, Inc. (HILS)?

As of Tue Apr 30 2024, market cap of Hillstream BioPharma, Inc. is 22.49 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HILS stock?

You can check HILS's fair value in chart for subscribers.

What is the fair value of HILS stock?

You can check HILS's fair value in chart for subscribers. The fair value of Hillstream BioPharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hillstream BioPharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HILS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hillstream BioPharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether HILS is over valued or under valued. Whether Hillstream BioPharma, Inc. is cheap or expensive depends on the assumptions which impact Hillstream BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HILS.

What is Hillstream BioPharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, HILS's PE ratio (Price to Earnings) is -2531.22 and Price to Sales (PS) ratio is 104.01 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HILS PE ratio will change depending on the future growth rate expectations of investors.